ALKERMES | ALKS - Выручка от реализации





Продажи Изменить Дата
AbbVie USD 15B 1.62B 2026-03
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
ALKERMES USD 392.91M 8.41M 2026-03
Amgen USD 8.62B 1.28B 2026-03
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 19.8B 500M 2026-03
Gilead Sciences USD 7B 930M 2026-03
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 246M 43M 2026-03
J&J USD 24.1B 500M 2026-03
Merck USD 16.29B 110M 2026-03
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Otsuka Holdings JPY 630.34B 19.81B 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Vertex Pharmaceuticals USD 2.99B 200M 2026-03